In a major advance for patients with Crohn's disease, a new study led by researchers at Mount Sinai Health System found that ...

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer's disease drug.

Tomorrows, a global health technology company that connects patients and physicians with pre-approval treatments, today published a new data report, entitled Searching for solutions: How physicians ...

Registered by the Federal Service for Supervision of Communications, Information Technology and Mass Communications.

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...

The rate of COVID-related intensive care unit (ICU) admissions was 9.2 per 1,000 person-years among patients who received a monovalent booster and 13.3 per 1,000 person-years for patients who ...

Tony Newberne is a high-risk multiple myeloma survivor. He is also a CPT, dietary manager, and patient advocate for several ...

A new study by a Tulane University researcher casts doubt on a widely used shortcut in rectal cancer drug trials, raising concerns that some treatments may be fast-tracked for approval without ...

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer's disease drug. They found that the drug slowed cognitive decline by 46% in a group of patients ...

Participants in trials of BrainStorm Cell Therapeutics' NurOwn filed a Citizens’ Petition with the FDA earlier this month ...

Pierre Fabre leads global development of tab-cel, an innovative therapy for EBV+ PTLD, with ongoing trials and potential FDA ...